Industry News
Biotechnology Industry News

Axsome’s migraine drug finally slated for FDA inspection but investors really want to know about stalled depression therapy
Axsome’s migraine drug finally slated for FDA inspection but investors really want to know about stalled depression therapy mbayer Tue, 02/08/2022 - 11:59
Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy
Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy mbayer Tue, 02/08/2022 - 11:59
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X ntaylor Tue, 02/08/2022 - 09:01
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling to leave ACTIV-3 future in doubt
Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling to leave ACTIV-3 future in doubt ntaylor Tue, 02/08/2022 - 08:06
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling in further blow to ACTIV-3
Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling in further blow to ACTIV-3 ntaylor Tue, 02/08/2022 - 08:06
Bristol Myers Squibb doles out $8M in new grants to improve health equity with cardiovascular, oncology focus
Bristol Myers Squibb doles out $8M in new grants to improve health equity with cardiovascular, oncology focus mbayer Mon, 02/07/2022 - 22:55
Congruence pulls in $50M series A to build a team of ‘drug hunters’ to go after rare disease targets
Congruence pulls in $50M series A to build a team of 'drug hunters' to go after rare disease targets ssorensen Mon, 02/07/2022 - 14:40
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patients
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patients klahucik Mon, 02/07/2022 - 10:04
Boundless Bio lures Berkley from Ionis to support clinical push
Boundless Bio lures Berkley from Ionis to support clinical push ntaylor Mon, 02/07/2022 - 09:01
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitor
CANbridge, targeting gaps in AstraZeneca's rare disease coverage, posts early-phase data on C5 inhibitor ntaylor Mon, 02/07/2022 - 08:02
Takeda joins Novartis and Merck in $45M funding for Koneksa Health
Takeda joins Novartis and Merck in $45M funding for Koneksa Health ssorensen Fri, 02/04/2022 - 13:13
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drug
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck's drug klahucik Fri, 02/04/2022 - 12:45
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal klahucik Fri, 02/04/2022 - 11:31
Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal klahucik Fri, 02/04/2022 - 11:31
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes klahucik Fri, 02/04/2022 - 09:59
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx ntaylor Fri, 02/04/2022 - 07:58
Remote possibilities: United BioSource teams with Seqster to boost decentralized study offering
Remote possibilities: United BioSource teams with Seqster to boost decentralized study offering aarmstrong Fri, 02/04/2022 - 07:56
Pfizer’s $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies
Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies ntaylor Fri, 02/04/2022 - 06:54
Unity once again lays off large number of staff, narrows focus to ophthalmology assets
Unity once again lays off large number of staff, narrows focus to ophthalmology assets klahucik Thu, 02/03/2022 - 16:32
Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved
Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved aarmstrong Thu, 02/03/2022 - 12:01

